Repligen Corporation (NASDAQ:RGEN) Director Acquires $201,834.00 in Stock

Key Points

• Martin D. Madaus, a director at Repligen Corporation, purchased 1,800 shares of the company's stock for a total of $201,834 at an average price of $112.13 per share.
• Repligen's latest quarterly earnings report revealed a 14.8% increase in revenue year-over-year, but earnings per share fell short of analysts' expectations.
• Most equities analysts currently rate Repligen with a consensus "Moderate Buy" and an average target price of $169.45.

Repligen Corporation (NASDAQ:RGEN - Get Free Report) Director Martin D. Madaus bought 1,800 shares of the company's stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director directly owned 1,800 shares of the company's stock, valued at approximately $201,834. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Repligen Stock Performance

NASDAQ:RGEN traded down $2.29 during trading hours on Friday, reaching $124.35. The stock had a trading volume of 574,823 shares, compared to its average volume of 1,060,907. The stock has a market cap of $7.00 billion, a P/E ratio of -497.38, a price-to-earnings-growth ratio of 2.33 and a beta of 1.05. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The stock has a 50 day simple moving average of $122.50 and a 200 day simple moving average of $132.99.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). The company had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. Repligen's revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.40 earnings per share. On average, research analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Repligen

Several hedge funds have recently made changes to their positions in RGEN. Price T Rowe Associates Inc. MD grew its position in shares of Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock valued at $1,027,165,000 after purchasing an additional 743,815 shares in the last quarter. Point72 Asset Management L.P. grew its position in Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock worth $132,227,000 after buying an additional 594,189 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Repligen by 3,219.3% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company's stock worth $51,422,000 after buying an additional 400,970 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in Repligen during the fourth quarter worth about $53,428,000. Finally, Raymond James Financial Inc. purchased a new position in Repligen during the fourth quarter worth about $52,492,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on RGEN shares. JPMorgan Chase & Co. dropped their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a report on Tuesday, April 29th. Evercore ISI dropped their price target on Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th. Royal Bank Of Canada lifted their price target on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a report on Wednesday, July 30th. Finally, Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $169.45.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.